Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 avr. 2026 18h14 HE | Source: AgomAb Therapeutics NV

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.
26 mars 2026 07h00 HE | Source: AgomAb Therapeutics N.V.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
08 janv. 2026 05h00 HE | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.